Медицинская литература. Новинки

 

 

 

 

 

 

Магнитно-резонансная томография печени с гепатотропными парамагнетиками в выявлении очаговой патологии печени и определении ее природы

Вы можете загрузить полный текст статьи в формате pdf

Описано применение методики МРТ с гепатотропным парамагнетиком для выявления и определения природы очаговых изменений печени в сравнении с МРТ с внеклеточными парамагнетиками и КТ с контрастным усилением. Показано, что МРТ с контрастированием гадоксетовой кислотой (Примовист®) имеет статистически достоверное преимущество (оно особенно выражено при ранней диагностике мелких очагов поражения печени) по сравнению с МРТ с внеклеточным контрастным препаратом или МСКТ с рентгеноконтрастным препаратом.

Ключевые слова:
гадоксетовая кислота, очаговые поражения печени, МРТ, КТ.

Литература:
1. Ягудина Р.И., Куликов, И.Ю. Зинчук А.Ю. и др. Фармакоэкономическое исследование применения различных контрастнысредств для лучевой диагностики
очаговых порaжений печени. Мед. виз. 2010; 3:
118–128
2. Кармазановский Г.Г., Шимановский Н.Л. Новая технология визуализации системы с помощью гепатотропного магнитно-резонансного контрастного средства
гадоксетата динатрия. Анн. хир. гепатол. 2007; 12 (4):
69–73.
3. Mahfouz A.E., Hamm B., Mathieu D. Imaging of metastases to the liver. Eur. Radiol. 1996; 6 (5): 607–614.
4. Newell J.D., Higgins C.B., Kelley M.J. et al. The influence
of hyperosmolalityon left ventricular contractile state: disparate effects nonionic and ionic solutions. Invest. Radiol.
1980; 15: 363–370.
5. Smith P.A., Klein A.S., Heath D.G. et al. Dual-phase spiral
CT angiography with volumetric 3D rendering for preoperative liver transplant evaluation: preliminary observations.
J. Comput. Assist. Tomogr. 1998; 22 (6): 868–874.
6. Solbiaty L., Cova L., Lerace T. et al. Liver cancer imaging:
the need for accurate detection of intrahepatic disease
spread. J. Comput. Assist. Tomogr. 1999; 23 (Suppl 1):
S29–S37.
7. Bellin M.F., Vasile M., MorelPrecetti S. Currently used
nonspecific extracellular MR contrast media. Eur. Radiol.
2003; 13: 2688–2698.
8. Bellin M.F., Webb J., Van Der Molen A. et al. Safety of MR
liver specific contrast media. Eur. Radiol. 2005; 15:
1607–1614.
9. Bluemke D.A., Sahani D., Amendola M. Efficacy and safety of MR imaging with liverspecific contrast agent: U.S.
multicenter phase III study. Radiology 2005; 237: 89–98.
10. Breuer J., Jung G., Poll L.W. et al. Imaging characteristics
of hepatocellular carcinoma using the hepatobiliary contrast agent GdEOBDTPA. Acta Radiol. 2006; 47: 5–23.
11. Huppertz A., Haraida S., Kraus A. et al. Enhancement of
focal liver lesions at gadotexetic acid – enhancement MR
imaging: correlation with histopathologic findings and spiral CT-nitial observations. Radiology 2005; 234: 468–478.
12. Jung G., Breuer J., Poll L. et al. Imaging of hepatocellular
carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta radiol. 2006; 47: 15–23.
13. Kolblinger C., BaSsalamah A., Langle F. et al. Gd-EOB-DTPA enhanced MR imaging versus triphasic CT:detection and classification of focal liver lesions. Eur. Radiol.
2006; 16 (1): 195.
14. Reimer P., Schneider G., Schima W. Hepatobiliary contrast
agents for contrast-enhanced MRI of the liver: properties,
clinical development and applications. Eur. Radiol. 2004;
14: 559–578.
15. Stroszczynski C., Gaffke G., Gnauck M. et al. Aktueller
Stand der MRTDiagnostik mit leberspezifischen
Kontrastmitteln Gd-EOB-DTPA und Gd-BOPTA. [Current
status of MRI diagnostics with liver-specific contrast
agents. Gd-EOB-DTPA and Gd-BOPTA] Radiologe 2004;
44: 1185–1191.
16. Zech C., Grazioli L., Jonas E. et al. Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced
MRI and 3phase MDCT in Germany, Italy and Sweden.
Eur. Radiol. 2009; 19 (3): S753–S763.
17. Zech C.J., Vos B., Nordell A. et al. Vascular enhancement
in early dynamic liver MR imaging in an animal model:
comparison of two injection regimen and two different
doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest. Radiol. 2009; 44: 305–310.
18. Motosugi U., Ichikawa T., Sou H. et al. Dilution method of
gadolinium ethoxybenzyl diethylenetriaminepentaacetic
acid (GdEOBDTPA-enhanced magnetic resonance
imaging (MRI). J. Magn. Reson. Imaging 2009; 30:
849–854.
19. Ringe K.I., Husarik D.B., Sirlin C.B., Merkle E.M.
Gadoxetate disodium-enhanced MRI of the liver: part 1,
protocol optimization and lesion appearance in the noncirrhotic liver. Am. J. Roentgenol. 2010;195 (1):13–28.
20. Tanimoto A., Lee J.M., Murakami T. et al. Consensus
report of the 2nd International Forum for Liver MRI. Eur.
Radiol. 2009;19 (Suppl. 5): S975–S989.
21. Ichikawa T., Saito K., Yoshioka N. et al. Detection and
characterization of focal liver lesions: a Japanese phase
III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in
patients with hepatocellular carcinoma and chronic liver
disease. Invest. Radiol. 2010; 45 (3): 133–141.

Magnetic-Resonance Tomography of Liver with Hepatotropic Paramagnetic for Diagnostics of Focal Lesions

It has been described the comparison study of MRI with hepatotropic paramagnetic, MRI with extracellular contrast media and CT with roentgen contrast media for diagnostics of liver lesions. According to obtained data MRI with gadoxetic acid (Primovist) has significant advantage (especially high for early diagnostics of small liver lesions) in comparison with MRI with extracellular contrast media and MDCT with roentgen contrast media.

Keywords:
gadoxetic acid, focal liver lesions, MRI, MDCT